The paper by Yan and colleagues takes aim at one of the nastiest versions of liver cancer: hepatocellular carcinoma, or HCC, that has grown into the portal vein and formed a portal vein tumor thrombus, usually shortened to PVTT.[1] In plain English, the cancer is not just sitting in the liver being rude. It is also invading one of the liver's most important blood highways.
That matters for two reasons. First, blocked portal flow can wreck liver function fast. Second, PVTT is a sign that the tumor has become aggressive, mobile, and very hard to control. Recent reviews describe this as a high-risk state where standard one-lane treatment often is not enough, which is why the field has been moving toward stacked approaches like immunotherapy plus targeted drugs plus local treatment.[3,4]
Now add the tumor microenvironment, which is science-speak for the neighborhood around the cancer. In HCC, that neighborhood can be deeply sketchy. T cells get exhausted. Macrophages can be recruited onto the wrong team. Immune checkpoints like PD-L1 act like fake security badges, telling immune cells, "Nothing to see here, move along."[5,6] Cancer, as usual, is running a bureaucratic scam.
Why a blood thinner is suddenly at the cancer meeting
Here is the twist. This paper argues that rivaroxaban, a blood thinner better known for preventing clots, might pull double duty in advanced HCC with PVTT.[1]
Why would that help? Because factor Xa, one of the clotting system's enzymes, may be doing more than making blood misbehave. A 2024 study in Journal for ImmunoTherapy of Cancer reported that factor Xa can push HCC cells toward immune escape by activating PAR-2 and boosting PD-L1 transcription through STAT2 signaling.[2] Translation: a clotting enzyme may also be helping tumors throw on an invisibility cloak.
That is the core idea here. If rivaroxaban blocks factor Xa, it might not only reduce portal vein thrombosis risk but also interfere with this FXa-PAR-2-PD-L1 pathway.[1,2] In theory, that could make T cells less sleepy and tumors less able to hide. For a disease where the immune system often looks like it got sent into the wrong group chat, that is not a small thing.
The authors are not proposing rivaroxaban as a solo hero in a trench coat. They are pitching it as a core adjuvant inside a longer-term "local-targeted-immune" strategy.[1] Think local therapy to hit the liver tumor, systemic therapy to pressure the cancer broadly, immunotherapy to wake up the body's defenses, and rivaroxaban to keep the vascular and immune sabotage from running wild. It is less silver bullet, more coordinated raid.
And honestly, that fits where the field is heading. A 2024 patient-level network meta-analysis found better outcomes with multimodality treatment strategies in advanced HCC with PVTT than with simpler approaches.[4] A 2026 review focused on immunotherapy in HCC with PVTT describes the same trend: selected patients may do better when clinicians combine immune therapy with HAIC, TACE, radiotherapy, or targeted agents rather than pretending one drug alone will clean up this whole mess.[3]
The catch, because there is always a catch
Important reality check. This new paper is a hypothesis-driven proposal, not a randomized clinical trial proving the strategy works.[1] That distinction matters. A lot.
Rivaroxaban is not candy. Patients with advanced HCC can have cirrhosis, varices, bleeding risk, portal hypertension, and fragile liver function. Adding an anticoagulant into that mix requires real caution, not vibes.[3] Also, even when immunotherapy works in HCC, responses can be uneven and the tumor microenvironment is wildly complicated.[5,6] Biology loves making things harder just when you thought you had a plan.
Still, the idea is worth paying attention to because it connects three problems that usually get discussed in separate rooms: clotting, immune suppression, and treatment resistance. This paper says they may be part of the same ugly machine.[1,2] If that holds up in prospective trials, rivaroxaban could become more than a supportive medication. It could become part of the actual anti-cancer strategy for one of the hardest-to-treat liver cancer scenarios.
That would be a big deal. Not because it sounds flashy. Because patients with advanced HCC and PVTT do not need flash. They need the plumbing cleared, the immune system re-armed, and the tumor to stop acting like it owns the building.
References
-
Yan Y, Zou D, Li Y, Ma H, Chen H. Enhancing immune response in advanced HCC with PVTT: rivaroxaban as a core adjuvant in combined therapy. J Immunother Cancer. 2026;14. DOI: 10.1136/jitc-2025-014060
-
Li X, Gao L, Wang B, et al. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription. J Immunother Cancer. 2024;12:e009565. DOI: 10.1136/jitc-2024-009565
-
Marzi L, Sacco R, Siciliani L, et al. Immunotherapy in hepatocellular carcinoma with portal vein tumour thrombosis: from poor prognosis to curative-intent strategies. Cancers (Basel). 2026;18(4):627. DOI: 10.3390/cancers18040627. PMCID: PMC12939993
-
Leung JH, Wang SY, Leung HWC, Chan ALF. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis. Front Oncol. 2024;14:1344798. DOI: 10.3389/fonc.2024.1344798. PMCID: PMC10905023
-
Seyhan D, Allaire M, Fu Y, et al. Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy. Cell Mol Immunol. 2025;22(10):1132-1158. DOI: 10.1038/s41423-025-01308-4
-
Sangro B, Chan SL, Meyer T, et al. Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2021;9:e002794. DOI: 10.1136/jitc-2021-002794
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.